Selpercatinib for RET-Altered Thyroid Cancer and MTC: Lori Wirth, MD

In this interview, Lori Wirth, MD, speaks with i3 Health about selpercatinib (RetevmoTM, Eli Lilly), which was recently approved by the FDA for the treatment of patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), advanced/metastatic RET-mutant medullary thyroid cancer (MTC), and advanced/metastatic RET fusion-positive thyroid cancer. Dr. Wirth, Medical Director of the Center for Head and Neck Cancers at Massachusetts General Hospital and first author of the phase 1/2...
Continue reading

Selpercatinib Approved for RET-Mutant NSCLC, Thyroid Cancer

The FDA has approved selpercatinib (RetevmoTM, Eli Lilly), for adult patients with metastatic RET-fusion—positive NSCLC, adult and pediatric patients 12 years of age or older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, and adult and pediatric patients 12 years of age or older with advanced or metastatic RET-fusion—positive thyroid cancer who require systemic therapy and are refractory to radioactive iodine. Selpercatinib is the first treatm...
Continue reading

Copyright © 2020 Oncology Data Advisor. All rights reserved.